NINGBO INNO PHARMCHEM CO.,LTD. is a dedicated supplier of high-quality chemical compounds essential for medical research and pharmaceutical development. Erlotinib Hydrochloride (CAS 183319-69-9) is a prime example of such a compound, recognized for its significant clinical impact as an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor. Its established role in treating advanced cancers has made it a vital agent in modern oncology.

The clinical utility of Erlotinib Hydrochloride is most prominently seen in its application for non-small cell lung cancer (NSCLC) patients harboring specific EGFR mutations. By precisely targeting these molecular alterations, it offers a more effective treatment strategy compared to conventional therapies. This precision allows for a better understanding of patient response based on genetic profiling, a cornerstone of precision medicine in cancer therapy.

Furthermore, Erlotinib Hydrochloride's use in combination therapies for pancreatic cancer adds to its clinical significance. This dual application highlights its broad therapeutic potential and its value as a key pharmaceutical ingredient for developing comprehensive treatment plans. The ongoing clinical trials and research exploring its efficacy in different cancer types and in combination with other agents are crucial for advancing the field of antineoplastic agent development.

For researchers and medical professionals, understanding the impact of Erlotinib Hydrochloride on EGFR signaling pathways is fundamental. Its role as an EGFR tyrosine kinase inhibitor provides a clear mechanism for intervention in cancers driven by EGFR activation. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting these critical areas of research by ensuring a consistent supply of Erlotinib Hydrochloride, facilitating advancements in non-small cell lung cancer treatment, pancreatic cancer therapy, and the broader study of EGFR gene mutation treatment.